12
Participants
Start Date
April 28, 2021
Primary Completion Date
November 21, 2025
Study Completion Date
November 21, 2025
LCI699
osilodrostat (LCI699) is in the form of tablets 1 milligram (mg), 5 mg, and 10mg or in form of capsules 0.1 mg, 0.2 mg, 0.5 mg, 1 mg or 5 mg, both the formulations for oral administration
RECRUITING
UZ Brussel, Jette
WITHDRAWN
University Clinical Center Ljubljana, Ljubljana
WITHDRAWN
Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna
RECRUITING
National Institute of Child Health and Human Development, Bethesda
RECRUITING
Aziendal Ospedaliero Universitaria Pisana Presidio Ospedale di Cisanello, Pisa
RECRUITING
Hospital Necker Enfants Malades, Paris
RECRUITING
Robert Debre Hospital, Paris
RECRUITING
University of California San Francisco UCSF, San Francisco
RECRUITING
CHU Bicetre APHP Paris Saclay, Paris
RECRUITING
Ospedale Bambino Gesu, Roma
WITHDRAWN
Alder Hey Childrens NHS Foundation Trust, Liverpool
RECRUITING
The Royal London Childrens Hospital, London
RECORDATI GROUP
INDUSTRY